HomeNewsBusinessiSPIRT likely to focus on bridging the technical gap in the BBMP bed allocation software

iSPIRT likely to focus on bridging the technical gap in the BBMP bed allocation software

The development comes in the light of widespread corruption in the BBMP’s bed allocation system, alleged by the Bengaluru South MP Tejasvi Surya. The BJP MP has reached out to Infosys chariman Nandan Nilekani to revamp the system. Think tank iSPIRT has also been roped in.

May 05, 2021 / 21:19 IST
Story continues below Advertisement
BJP MP Tejasvi Surya, on March 13 launched a new version of the Covid Raksha helpline for residents of Bengaluru South.
BJP MP Tejasvi Surya, on March 13 launched a new version of the Covid Raksha helpline for residents of Bengaluru South.

Bengaluru's startup and technology community has stepped up to solve a critical problem that the city is grappling with - an efficient system of bed allocation as it continues to see a huge spike in the number of people testing positive for Coronavirus.

Bengaluru South MP Tejasvi Surya who alleged corruption in the way civic body BBMP was allocating beds for patients, said he has sought help from Infosys co-founder and Aadhaar architect Nandan Nilekani to revamp the bed allocation software. Nilekani has drafted tech architects from policy think tank iSpirt to make the bed booking software more transparent and efficient.

Story continues below Advertisement

iSPIRT likely to focus on bridging the technical gap in the BBMP bed allocation software

Moneycontrol learns that iSPIRT is likely to help with bridging technical gaps in the BBMP’s bed allocation software as per its current assessment. People familiar with the development said the think tank is currently taking stock of the systems and has seen huge response from the startup and tech community in Bengaluru.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show